A brief look at the medical issues in the Charlie Gard case – ABC News

Charlie Gard is a terminally ill British child whose parents are fighting for the right to take him to the United States for an experimental treatment. His case has gained international attention, including from Pope Francis and U.S. President Donald Trump.

The 11-month-old is being treated at London's Great Ormond Street Hospital, which maintained the experimental treatment was "unjustified" and might cause Charlie more suffering without doing anything to help him. The hospital planned to take the boy off life support, but petitioned for a new court hearing based on evidence from researchers at the Vatican's children's hospital and another facility outside of Britain.

Below is some background on the medical and legal issues behind Charlie's case:

WHAT IS MITOCHONDRIAL DISEASE?

Mitochondrial disease is the umbrella term for a number of rare conditions caused by genetic mutations that result in the failure of mitochondria, specialized compartments within most cells that supply the energy needed to sustain life and support organ function. When mitochondria fail, cells can be injured or die, causing organ systems to shut down. The brain, heart, muscles and lungs are most affected because they need the most energy.

Charlie suffers from a form of the disease known as infantile onset encephalomyopathic mitochondrial DNA depletion syndrome (MDDS.) It is specifically known as the RRM2B mutation of MDDS. There is no known cure.

WHAT IS THE TREATMENT HIS PARENTS WANT FOR CHARLIE?

Doctors in the United States have been experimenting with a treatment known as nucleoside therapy, which has shown success in reducing the symptoms of some types of mitochondrial disease in laboratory mice. The treatment has been administered to a small number of children who have also shown improvement.

However, the treatment has never been used on either mice or humans with the type of mitochondrial disease from which Charlie suffers, according to court documents.

HAS THE NUCLEOSIDE THERAPY BEEN USED BEFORE?

A boy named Arturito Estopinan in Baltimore was the first child to be given deoxynucleotide monophosphate, an experimental treatment that significantly extended the life of mice with the same condition as Arturito, known as TK2-related mitochondrial depletion syndrome.

Art Estopinan, the boy's father, met with Charlie's parents in London to share his experience. He stressed that while the therapy was a treatment, not a cure, his 6-year-old son was "getting stronger every day." Arturito still needs around the clock care. Estopinan and his wife, Olga, have given their lives over to caring for him, hoping that a cure will come one day. The sacrifices keep coming because "we love our son," he said.

"A lot of very smart doctors are unaware of these experimental medications," Estopinan said. "As a father, I cannot sit back and know that my son was saved and not be vocal in support of Charlie Gard receiving these meds."

A CRUEL DISEASE

Sian Harding, Director of the British Heart Foundation Cardiovascular Regenerative Medicine Center at Imperial College, described the difficulty of treating the disease that Charlie has.

"Mitochondrial diseases are cruel because they strike babies and young children, who rapidly deteriorate," Harding said. "It is because there is no cure that the scientific and medical community have concentrated on pre-conception mitochondrial therapy, and it has been an enormous advance that this is now licensed by the government. It allows parents with these mutations to have healthy children, though sadly, cannot help babies already born."

WHY IS IT UP TO THE COURTS AND NOT CHARLIE'S PARENTS?

Parents in Britain do not have the absolute right to make decisions for their children. It is normal for courts to intervene when parents and doctors disagree on the treatment of a child. The rights of the child take primacy, with the courts weighing issues such as whether a child is suffering and how much benefit a proposed treatment might produce.

Professor Dominic Wilkinson, director of medical ethics at the Oxford Uehiro Center for Practical Ethics, said decisions about life-sustaining treatment for a child are "fraught."

"Sadly, reluctantly, doctors and judges are justified in concluding that continuing life support is not always helpful for a child and is in fact doing more harm than good," Wilkinson said. "Providing comfort, avoiding painful and unhelpful medical treatments, supporting the child and family for their remaining time: sometimes that is the best that we can do, and the only ethical course."

Link:

A brief look at the medical issues in the Charlie Gard case - ABC News

Far More People Than Thought Are Carrying Rare Genetic Diseases – ExtremeTech

Outside of evolutionary biology, the human body is often spoken of as a miracle of engineering. But those more familiar with its workings point out evolution is no perfectionist, often favoring clunky ad hoc solutions over thosemore elegant in design. In fact, the comparison of evolution to a gambler might be the most apt, and nowhere is this more evident than in reference to genetic diseases like hemophilia. Now a recent study published in the Annals of Internal Medicine suggests far more people than previously thought are carrying variants of rare genetic diseases and could force us to redefine what is considered a healthy genome.

Genetic disorders are those resulting from mutations in ones DNA, often with horrendous results. Previously, scientists believedgenetic disorders were present in only a small fraction of the human population, 5 percent or less. After all, a population riven with genetic mistakes would quickly die out, or so went the logic. However, the present study puts the fraction of people with mutations linked to genetic diseases at something closer to 20 percent.

But is nature really so clumsy as to allow a veritable swarm of deleterious mutations to slip through her quality control mechanisms? It turns out many genetic disorders hide secret advantages. Take a person with the mutation that causes sickle cell anemia. A single copy of the mutation for sickle cellanemiaactually protects against the disease malaria. Its only if someone receivestwo copies of the defective gene that the problematic form of sickle cellanemia results. With many genetic disorders, nature seems to be hedging her bets, allowing some defects to slip through if they can provide a survival advantage to the population at large.

Counterintuitively, an individual suffering from a rare genetic disease may represent a successful population-level response to a given environment. This dance between genes and environments is at the heart of what we think of as health. But for most of history, medicine has considered the well being of an individual in isolation from population-level genetics. A more nuanced understanding of rare genetic diseases would take into account the various benefits genetic mistakes confer. This also suggests a cautious approach when editing our own genomes with tools like tools like CRISPR. Even seemingly terrible mutations we would be tempted to eliminate from the genetic pool may confer some secret advantage geneticists have yet to discover.

The study comes at a time when routine genetic testing is the subject of a far-ranging debate. Many doctors fear the release of genetic data to patients would cause undue anxiety. This study didnt support those claims, and goes a distance to undermine the paternalistic style of medicine currently practiced in many developed nations. In the United States, for instance, doctors remain a crucial chokepoint through which patients must pass through to access genetictesting. That said, anumber of direct-to-consumer genetic testing companies like 23andMe are breaking down these barriers, and a host of websites and even smartphone apps exist to help one make sense of their genetic data.

Now read: What is gene therapy?

Excerpt from:

Far More People Than Thought Are Carrying Rare Genetic Diseases - ExtremeTech

Largest genome-wide study of lung cancer susceptibility conducted – The FINANCIAL

The FINANCIAL -- A new study conducted by an international team of lung cancer researchers, including Professor John Field from the Universitys Institute of Translational Medicine, have identified new genetic variants for lung cancer risk.

Lung cancer continues to be the leading cause of cancer mortality worldwide. Although tobacco smoking is the main risk factor, variations in a persons genetic makeup has been estimated to be responsible for approximately 12% of cases. However, the exact details of these variations have been previously unknown.

Genotyping is the process of determining differences in the genetic make-up (genotype) of an individual by examining the individuals DNA sequence.

Largest study of this type

By gathering genotype data from different studies around the world, through the use of a special research platform called OncoArray, researchers were able to increase the sample size for this study making it the largest one of its type in the world. The Liverpool Lung Project, funded by the Roy Castle Foundation, has made a major contribution to this international project.

Researchers examined the data to identify the genetic variants associated with lung cancer risk.

During the study, published in Nature Genetics, more than 29,200 lung cancer cases and more than 56,000 samples taken from people without lung cancer (controls) were examined. Researchers identified 18 genetic variations that could make people more susceptible to lung cancer and also 10 new gene variations.

Better understanding

Professor John Field, Clinical Professor of Molecular Oncology and the Chief Investigator of the UK Lung Cancer Screening Trial, said: This study has identified several new variants for lung cancer risk that will translate into improved understanding of the mechanisms involved in lung cancer risk.

Samples taken from the major Liverpool Lung Project, funded by the Roy Castle Foundation, was conducted by experts at the University of Liverpool, were used in this study.

These results will help us to further improve the way we can screen for lung cancer in high risk individuals in the UK. Further studies will help in the targeting of specific genes to influencing lung cancer risk, smoking behaviour and smoking effects on brain biology.

Exciting

The co-lead of the study was Christopher Amos, Chair and Professor of Biomedical Data Science, Professor of Community and Family Medicine, and Professor of Molecular and Systems Biology at Dartmouths Geisel School of Medicine, and interim Director and Associate Director for Population Sciences at Dartmouths Norris Cotton Cancer Centre. Of the study he said: What is particularly exciting is the magnitude of the study along with the new findings of genes influencing lung cancer which have not previously been reported.

This study definitely leads to new ideas about mechanisms influencing lung cancer risk.

Continued here:

Largest genome-wide study of lung cancer susceptibility conducted - The FINANCIAL

Can Genetic Engineering Put an End to Diamondback Moth Plague … – Growing Produce

Florida Struggling to Stay Afloat in Wake of Drought

USDA Invests $6.8 Million for Pollinator Health

The diamondback moth (DBM) is a pest of epic proportions to farmers worldwide. Growers of cabbage and collard crops know this all too well. Controlling the notorious DBM has become more difficult in recent times with incidence of pesticide resistance increasing. With that, the search for viable management continues to expand. For the last two years, Cornell scientists have been working with British-based biotech company Oxitec and testing its self-limiting gene capabilities on DBM in a protected environment. The team at Cornell has been waiting for a go-aheadfrom USDA to take the experiment out from behind closed doors and into one if its cabbage fields in Upstate New York. It looks like the wait is over.

USDAs Animal and Plant Health Inspection Service (APHIS) has officially announced the availability of a final environmental assessment and finding of no significant impact and will concurrently issue a permit for the field release of a genetically engineered DBM.

The pest moths are genetically engineered for repressible female lethality and to express red fluorescence as a marker. The purpose of the field release is to assess the feasibility and efficacy of these moths in reducing populations of DBM. Based on the finding of no significant impact, APHIS has determined that an environmental impact statement need not be prepared.

Notice of these actions will be published in theFederal Register.

The Northeast Organic Farming Association of New York (NOFA-NY) has since released a statement denouncing USDAs decision. A portion of the statement reads as follows: NOFA-NY considers the release of a novel genetically engineered organism to be a major activity with potentially significant and heretofore unknown health and environmental effects, said NOFA-NY Policy Advisor Liana Hoodes. It is now up to New York State Department of Environmental Conservation (DEC) to ensure the safety of its citizens before granting the necessary state permit. We call on the NYS DEC to require a full environmental impact statement and public hearings during a complete review under State Environmental Quality Review Act.

Read more here:

Can Genetic Engineering Put an End to Diamondback Moth Plague ... - Growing Produce

Gene therapy in hemophilia advances with big drops in patient bleeding rates – STAT

He wants to sell you a $300 fasting diet

He wants to sell you a $300 fasting diet to prolong your life. It might not

Essentially witchcraft: A former naturopath takes on her colleagues

Essentially witchcraft: A former naturopath takes on her colleagues

Facing bleak odds, cancer patients chase one last chance

Facing bleak odds, cancer patients chase one last chance in Cuba

U.K. pharma trade group sues government over new drug

U.K. pharma trade group sues government over new drug cost test

Pharmalittle: FDA has new opioid plan; Amicus gets a

Pharmalittle: FDA has new opioid plan; Amicus gets a win; Justice guts health care fraud unit

In rare move, FDA reverses course on drug developed

In rare move, FDA reverses course on drug developed by CEO with ties to Trump

Read the original post:

Gene therapy in hemophilia advances with big drops in patient bleeding rates - STAT

First gene therapy ‘a true living drug’ on the cusp of FDA approval – Washington Post

PHILADELPHIA When doctors saw the report on Bill Ludwigs bone-marrow biopsy, they thought it was a mistake and ordered the test repeated. But the results came back the same: His lethal leukemia had been wiped out by an experimental treatment never used in humans.

We were hoping for a little improvement, remembers the 72-year-old retired New Jersey corrections officer, who had battled the disease for a decade. He and his oncologist both broke down when she delivered the good news in 2010. Nobody was hoping for zero cancer.

The pioneering therapy with Ludwig and a few other adults at the University of Pennsylvania hospital paved the way for clinical trials with children. Six-year-old Emily Whitehead, who was near death, became the first pediatric recipient in 2012. Like Ludwig, she remains cancer-free.

Such results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration. An FDA advisory committee will decide Wednesday whether to recommend approval of the approach, which uses patients own genetically altered immune cells to fight blood cancers.

If the panel gives the nod, the agency probably will follow suit by the end of September. That would open the latest chapter in immunotherapy a true living drug, says Penn scientist Carl June, who led its development.

The CAR T-cell treatment, manufactured by the drug company Novartis, initially would be available only for the small number of children and young adults whose leukemia doesnt respond to standard care. Those patients typically have a grim prognosis, but in the pivotal trial testing the therapy in almost a dozen countries, 83 percent of patients went into remission. A year later, two-thirds remained so.

And childhood leukemia is just the start for a field that has attracted intense interest in academia and industry. Kite Pharma of Santa Monica, Calif., has applied for FDA approval for aggressive non-Hodgkin lymphoma, and a similar Novartis application is close behind. Researchers also are exploring CAR T-cell therapys use for multiple myeloma and chronic lymphocytic leukemia, the disease that afflicted Ludwig. Theyre also tackling a far more difficult challenge using the therapy for solid tumors in the lungs or brain, for example.

The excitement among doctors and researchers is palpable. Were saving patients who three or four years ago we were at our wits end trying to keep alive, said Stephen Schuster, the Penn oncologist who is leading a Novartis lymphoma study. Both the study and a Kite trial have shown that the treatment can put about one-third of adults with advanced disease those who have exhausted all options into remission.

Yet along with the enthusiasm come pressing questions about safety, cost and the complexity of the procedure.

It involves extracting white blood cells called T cells the foot soldiers of the immune system from a patients blood, freezing and sending them to Novartiss sprawling manufacturing plant in Morris Plains, N.J. There, a crippled HIV fragment is used to genetically modify the T cells so they can find and attack the cancer. The cells then are refrozen and sent back to be infused into the patient.

Once inside the persons body, the T-cell army multiplies astronomically.

Novartis hasnt disclosed the price for its therapy, but analysts are predicting $300,000 to $600,000 for a one-time infusion. Brad Loncar, whose index fund focuses on cancer immunotherapy treatment, hopes the cost doesnt prompt a backlash. CAR-T is not the EpiPen, he said. This is truly pushing the envelope and at the cutting edge of science.

The biggest concerns, however, center on safety. The revved-up immune system becomes a potent cancer-fighting agent but also a dangerous threat to the patient. Serious side effects abound, raising concerns about broad use.

Treating patients safely is the heart of the rollout, said Stephan Grupp of the Childrens Hospital of Philadephia, who as director of its Cancer Immunotherapy Program led early pediatric studies as well as Novartiss global trial. The efficacy takes care of itself, but safety takes a lot of attention.

One of the most common side effects is called cytokine release syndrome, which causes high fever and flulike symptoms that in some cases can be so dangerous that the patient ends up in intensive care. The other major worry is neurotoxicity, which can result in temporary confusion or potentially fatal brain swelling. Juno Therapeutics, a biotech firm in Seattle, had to shut down one of its CAR T-cell programs because five patients died of brain swelling. Novartis has not seen brain swelling in its trials, company officials said.

To try to ensure patient safety, Novartis isnt planning a typical product rollout, with a drug pushed as widely and aggressively as possible. The company instead will designate 30to 35 medical centers to administer the treatment. Many of them took part in the clinical trial, and all have gotten extensive training by Grupp and others.

Grupp said he and his staff learned about the side effects of CAR T-cell therapy and what to do about them through terrifying experience that began five years ago with Emily Whitehead.

The young girl, who had relapsed twice on conventional treatments for acute lymphoblastic leukemia, was in grave condition. Grupp suggested to her parents that she become the first child to get the experimental therapy.

I said, Surely, this has been tried on kids somewhere else in the world, recalled her father, Thomas Whitehead of Philipsburg, Pa. But Steve said, Nope, some adults got it, but that was a different kind of leukemia.

After getting the therapy, Emilys fever soared, her blood pressure plummeted, and she ended up in a coma and on a ventilator for two weeks in the hospitals intensive care unit. Convinced his patient would not survive another day, a frantic Grupp got rushed lab results that suggested a surge of interleukin 6 was causing her immune system to relentlessly hammer her body. Doctors decided to give Emily an immunosuppressant drug called tocilizumab.

She was dramatically better within hours. She woke up the next day, her 7th birthday. Tests showed her cancer was gone.

The approval of CAR T-cell therapy would represent the second big immunotherapy advance in less than a decade. In 2011, the FDA cleared the first agent in a new class of drugs called checkpoint inhibitors. It has approved four more since then.

There are big differences between the two approaches. The checkpoint inhibitors are targeted at solid tumors, such as advanced melanoma, lung and bladder cancer, while CAR-T cell therapy has been aimed at blood disorders. And although checkpoint inhibitors are off the shelf, with every patient getting the same drug, the other is customized to an individual. Many immunotherapy experts think the greatest progress against cancer will occur when researchers figure out how to combine the approaches.

For the Penn team, the CAR T-cell story goes back decades, starting at the then-National Naval Medical Center in Bethesda, where June and a postdoc fellow named Bruce Levine worked on new HIV treatments. In the process, they figured out a way to turbocharge T cells to make them more powerful and plentiful.

The pair moved to Philadelphia in 1999 and dove into cancer research. Two years later, Junes wife died of ovarian cancer, something he has credited as spurring him to work even harder in the field. In the years that followed, researchers across the country, including at Memorial Sloan Kettering Cancer Center in New York and Fred Hutchinson Cancer Research Center in Seattle racked up an array of tantalizing discoveries involving T cells.

Fast-forward to 2010, when Ludwig, who lives in Bridgeton, N.J. became Penns first patient to receive CAR T-cell therapy. Two other men got the treatment not long after. One is still in remission; the other relapsed and died.

But after those three patients, the Penn researchers ran out of money for more treatments. To try to raise interest and funding, they decided to publish the results of their work. The article that appeared in the New England Journal of Medicine in August 2011 created a firestorm, June said one that brought them new resources. David Porter, a Penn oncologist working with June, was on vacation in western Maryland and had to stop at a Kohls to buy a dress shirt for the immediate TV interviews.

The pediatric trial opened the following spring with Whitehead. Six months later, Penn licensed its technology to Novartis in exchange for financial support, which included a new cell-manufacturing facility on campus.

With FDA approval seeming imminent, the researchers who were so instrumental in the therapys development and testing are almost giddy. Grupp is especially pleased that the advance will be available first to children. Usually everything is developed first for adults, he noted recently, and children are an afterthought.

Read more:

This is not the end: Using immunotherapy and a genetic glitch to give cancer patients hope

This 8-year-old is free of cancer for now after a breakthrough treatment

For a 6-year-old with cancer, a future staked on medicines hottest field

Read this article:

First gene therapy 'a true living drug' on the cusp of FDA approval - Washington Post

Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells – Technology Networks

A new method efficiently transfers genes into cells, then activates them with light. This could lead to gene therapies for cancers

Mineko Kengaku, Tatsuya Murakami, and their colleagues from Kyoto Universitys Institute for Integrated Cell-Material Sciences (iCeMS) have developed a new method that modifies the surface of nanorods, making them more efficient in transporting cancer-killing genes into cells.

The method involves coating gold nanorods, which produce heat when exposed to a near-infrared laser, with the lipids oleate and DOTAP. The lipids enhance the nanorods' ability to interact with and penetrate cells.

The team also developed a gene carrier, known as a plasmid vector, which includes a heat shock protein that is activated in response to heat.

First, the vector was bound to the enhanced green fluorescent protein (EGFP) gene, and then transferred into mammalian cells by the lipid-coated gold nanorods. Exposing cells to near-infrared laser for ten seconds heated up the gold nanorods, turning on the EGFP gene. Surrounding, non-targeted cells showed little to no EGFP expression.

A protein called TRAIL was then added to the plasmid vector. TRAIL induces cell death in cancer cell lines. Infrared illumination of cells transfected by TRAIL-carrying nanorods led to a high cell death rate in surrounding cancer cells.

The lipid-coated gold nanorods could potentially help with molecular cancer therapies.

This new system provides a unique opportunity for site-directed, light-inducible transgene expression in mammalian cells by a near-infrared laser, with minimal phototoxicity, conclude the researchers in their study published in the journal Scientific Reports.

This article has been republished frommaterialsprovided by Kyoto University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Nakatsuji, H., Kawabata, G. K., Kurisu, J., Imahori, H., Murakami, T., & Kengaku, M. (2017). Surface chemistry for cytosolic gene delivery and photothermal transgene expression by gold nanorods. Scientific reports, 7(1), 4694.

Visit link:

Breakthrough Nanorod Tech Could Deliver Gene Therapy Directly to Cancer Cells - Technology Networks

Pioneering gene therapy patients stay on track, boosting Spark’s … – Endpoints News

After rattling investors with early signs of an immune reaction in a couple of cases as well as an unexpected infusion for a suspected knee bleed, Spark Therapeutics $ONCE says that its early Phase I/II study for its hemophilia B gene therapy is staying on track, slashing the rate of annual infusions and the bleed rate among the 10 patients on the pioneering therapy SPK-9001.

The annual infusion rate has new dropped 99%, down to a mean of 1 compared to 67.5 ahead of treatment. Five of the 10 are now past the one-year mark since their treatment, with no bleeding issues. The group of 10 posted an average bleed rate of 0.4 compared to 11.1 ahead of once-and-done therapy.

Singling out the first patient, whos now past the 18-month mark, researchers say hes had zero bleeds with no Factor IX infusions. Both cases of elevated liver enzymes indicating an immune response to the delivery vector were resolved with steroids and neither have had bleeds or the need for infusions.

Spark has now accumulated close to 10 years of patient responses to its therapy, an important first step in laying out the potential for gene therapy to end hemophilia.

The latest update arrived at a scientific conference in Berlin marked by the dramatic showdown between Shire and its rival Roche, which fielded more newly contested boasts about its would-be hemophilia blockbuster emicizumab. Alnylam and Sanofi also stepped up with a promising look at the latest Phase II data on their RNAi approach underscoring some significant gains in the field for a variety of new approaches to the rare blood disorder.

We continue to be encouraged by the SPK-9001 clinical trial results observed to date, with all participants having discontinued routine infusions of factor IX concentrates, said Katherine A. High, M.D., president and chief scientific officer at Spark Therapeutics. The growing body of data showing a sustained response is a promising sign for this investigational hemophilia B gene therapy program.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

See more here:

Pioneering gene therapy patients stay on track, boosting Spark's ... - Endpoints News

uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene … – GlobeNewswire (press release)

July 11, 2017 06:30 ET | Source: uniQure N.V.

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 11, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented new clinical data demonstrating that the presence of pre-existing anti-AAV5 neutralizing antibodies (NABs) does not predict the potential efficacy of AAV5-mediated gene transfer in patients with hemophilia B. Clinically meaningful factor IX (FIX) activity levels from the ongoing Phase I-II trial of AMT-060 were observed at NAB titers up to 1:341, determined as corresponding up to the 90th percentile of a healthy control population. NABs were quantified in the blood sera of these patients using a highly sensitive assay. These clinical data were presented today in a poster presentation at the 26th Biennial Congress of theInternational Society on Thrombosis and Hemostasis(ISTH), taking place this week in Berlin, Germany.

The presence of pre-existing NABs to adeno-associated virus (AAV) vectors has long posed a critical challenge for the clinical application of gene therapies, as patients who currently screen positive for NABs are generally excluded from treatment. Researchers from uniQure recently presented data in non-human primates suggesting that AAV5 could successfully mediate gene transfer in the presence of NABs at levels as high as 1:1031.

In a poster presentation at the ISTH meeting, a re-analysis was described of pre-gene transfer screening samples from the 10 patients who have been treated in the ongoing Phase I/II trial of AMT-060 for hemophilia B. The patients had tested negative for preexisting anti-AAV5 NAbs using a green fluorescent proteinbased (GFP) assay before receiving treatment. These samples were later re-assessed using a highly sensitive luciferase-based (LUC) NAB assay. Anti-AAV5 NABs were detected retrospectively in three patients who had been treated with the low dose (5x1012 gc/kg) of AMT-060. However, all three patients presented increases in FIX expression and, especially, the patient with the highest NAB level (titer 1:341) had the highest FIX-activity (steady-state FIX 6.8% of normal; latest FIX measurement 10.7% of normal) among all five patients treated in the low-dose cohort. None of the three patients who tested positive for NAB titers, experienced over time elevations in liver enzymes post gene transfer, FIX activity loss, or clinically relevant T-cell responses to the capsid.

These clinical data show that hemophilia B patients presenting with neutralizing antibodies may be considered eligible for AAV5-mediated gene transfer, stated Matthew Kapusta, chief executive officer at uniQure. This development potentially expands the applicability of AAV5 gene therapies to nearly all hemophilia B patients. We believe these factors contribute to making AAV5 a potential best-in-class vector for delivering gene therapies more effectively and safely to a greater portion of patients in need of treatment.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntingtons disease and cardiovascular diseases. http://www.uniQure.com

uniQure Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, including the future development of AMT-060, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with corporate reorganizations and strategic shifts, collaboration arrangements, our and our collaborators clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQures 2016 Annual Report on Form 10-K filed on March 15, 2017. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Related Articles

Lexington, Massachusetts, UNITED STATES

Visit link:

uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene ... - GlobeNewswire (press release)

The Futurist: Why HR and IT need to be closer – Human Resources Online

HR and IT functions need to keep helping each other to identify gaps in employee working patterns that require attention, says Usha Baidya, vice-president, human resources, Asia Pacific, Middle East and Africa, BT.

Technology has brought comprehensive changes to the way companies operate and is now integral to every department especially HR. BT has a strong history of investment in HR technology and we host a global portal for all our HR systems, processes and policies.

Over the years, HR technology has brought significant improvements to businesses. Gone are the days when HR systems were only used to hold employee data, payroll and recruitment information.

These days, HR departments dont even have to create their own recruitment software. HR functions can now connect cloud-based HR systems to social networks to acquire talent in competitive markets.

We have entered a new wave of HR technology and the role and function of HR continues to change and evolve. Business leaders are requesting real-time employee insights on the go and HR departments need to be ready to meet this demand in real-time.

This is particularly important as HR technology is no longer a simple tool just to make HR processes more efficient, but also used by different teams within an organisation to make strategic decisions.

According to BTs 2016 Mobile Multiplier Study, nearly 80% of employees want to work either remotely or from home, via technology. Without this capability, dissatisfaction levels will rise and they may eventually consider leaving the company.

Employees also need accurate and reliable information in real-time and on-demand to perform their tasks efficiently and effectively so technology has an important role in equipping people with the tools that allow them to do their job easily.

HR and IT functions need to keep helping each other to identify gaps in employee working patterns that require attention, whether via changes in processes, systems or tools.

Close collaboration between HR and IT departments also allows both teams to be aware of employee usage behaviour and how data security threats can be avoided well ahead of time, by finding the right tools that serve the desired workplace requirements.

In the future, HR leaders need to focus on building digital HR strategies and roadmaps. There are lots of HR systems, products and apps available in the marketplace, which allow leaders to focus on productivity, employee engagement, innovation, team work, collaboration and coaching.

As a HR function, we need to be on the front foot and develop advanced predictive models and data analytics to meet the changing demands of those managing an agile and mobile workforce.

The June 2017 issue of Human Resources magazine is a special edition, bringing you interviews with 12 HR leaders, with their predictions on the future of HR.

ReadThe Futuristor subscribe here.

Need some guidance to help you lead the way? These soundbites should remind you to keep developing yourself, as well as others. ..

Employers in Singapore are expecting their payroll to grow or stay the same this quarter, with just 2% expecting a decrease. ..

Despite the rising recruitment trend, not everyone agrees that social media is the way forward. ..

Your weekly update on job movements in HR - featuring changes from SP Setia, ANZ, HSBC, SAP Ariba, HRnet One, and more...

Rising costs and increasing competition have caused a drop in Singapore's small business confidence levels. ..

See original here:

The Futurist: Why HR and IT need to be closer - Human Resources Online

Futurist Jack Uldrich to Speak on Top Ten Future Trends for Leading IT Advocate – WireUpdate

Jul 10, 2017 - (Newswire)

Solving problems before your customers even know they have the problem is a laudablegoal. How can an organization do that? Jack Uldrichsays, "Start thinking like a Futurist."

Global Futurist Jack Uldrichis a distinguishedspeaker and best-sellingauthor. He travelsthe world speaking on future trends in a myriad of industries including education, finance, healthcare, agriculture, energy, and transportation.

"Thinking like a futurist involves appreciating how the world of tomorrow is changing. Far toooften companies are fixated on issues that are only front and center; or at times, they are stuck dealing with issues from the past. They aren't taking time out to reflect on what the future will hold in store."

Today, Uldrichwill address a leadinginfrastructure solution provider here in the Twin Cities. His audience will consistof Tech Management Specialists as well as Technologists in several industries including healthcare.

He will deliver his keynote: Foresight 20/20: Ten Game-ChangingTechnological Trends Transforming the world of Tomorrow.

The talk, based on his most recent bookForesight 20/20,will focus on advances in mobile web video communications, virtual and augmented reality, social media, robotics, gaming dynamics, renewable energies, "Big Data," the Internet of Things, as well as cybersecurity advances. He will also delve into quantum computing and how it will continue to drive seismic change and deliver paradigm-shattering transformation to nearly every facet of society.

Uldrich says, "Thinking like futuristsrevolves around these basic tenets: understanding the trends transforming the world of tomorrow;takingaction in the face of uncertainty; developing an appreciation for humility and embracing the concept that unlearning is as important as learning when it comes to future trends."

Most importantly Uldrichwantshis audiencemembersto adopt new open mindsets and to begin acquiringthe tools to create the future themselves.

Following his talk in Minneapolis, Uldrichwill be off toconducta three-day experiential leadership seminar based on leadership lessons of Meriwether Lewis and William Clark in Great Falls, Montana.

Parties interested in learning more aboutJack Uldrich, his books, his daily blog or his speaking availability are encouraged to visit hiswebsiteor to contactAmy Tomczykat amy@jackuldrich.com.

Original Source: https://www.newswire.com/news/futurist-jack-uldrich-to-speak-on-top-ten-future-trends-for-leading-it-19664529

Read more:

Futurist Jack Uldrich to Speak on Top Ten Future Trends for Leading IT Advocate - WireUpdate

Wall Street Expert Predicts Bitcoin Will Reach $55,000 in 5 Years – Futurism

In Brief In a time of financial instability, many individuals are turning to the decentralized bitcoin to store their wealth. Due to this as well as its potential to revolutionize the finance system, bitcoin has enjoyed stratospheric growth in recent years. Modern Gold

Tom Lee, a Wall Street strategist who works at Fundstrat, has predictedthat the price of bitcoin will continue its exponential rise until it reaches $55,000 by 2022. He bases his prediction on the economic principles of scarcity and market instability.

Lee argues, essentially, that bitcoin is subsuming the role that gold previousplayed in the economy. It has become a solid and dependable store of wealth in a time when we have seen recessions and market turbulence effecting peoples savings in their own currency. This is particularly the case in countries where the government controls the currency to achieve a desired effect, as is the case in China and Japan.

Many have criticized bitcoin for its turbulence it has now reached a volatility of 75 percent and argue that, for this reason, it cannot be the safe store of value that Lee sees it as. Lee, though, told Coin Telegraph that golds volatility approached 90 percent from 1971 to 1980 as the U.S. abandoned the gold standard hence, we expect this [bitcoins volatility] to improve over time. Coincidentally, bitcoin exceeded the value of gold earlier this year.

Bitcoins rise has been so meteorotic that it is quite unlike any other currency or asset, depending on who you ask in recent memory. To give a quirky example, in May of 2010, a developer bought two pizzas for 10,000 bitcoin. These, in total,would now be worth around $25 million, which is enough to buy a 720-year-old Magna Carta given that one sold for$21 million in 2007.

Bitcoin arguably lead the vanguard for cryptocurrenies moving from a quirky financial system in tight-knit tech communities to a talking point for major financial planners. It is now fundamentally changing the way we look at economiesin addition tobeing the leading example of blockchain technology.Simon Taylor, co-founder of a blockchain venture capital fund,said in an interview with Government Office for Science that the techbrings us near instant asset transfer, asset movement, and security of data movement, and that blockchainwill have a similar effect on exchange that the internet did on communication.

Bitcoin has now become large enough for entire countries to consider upending transaction systems that have been in place since the advent of currency itself.India and Sweden in particular are looking to mimic the systems to produce the first cashless societies in modern history. This is perhaps the ultimate testament to how significant the cryptocurrencyhas become.

Go here to read the rest:

Wall Street Expert Predicts Bitcoin Will Reach $55,000 in 5 Years - Futurism

Jaguar is Releasing its Tesla Rival in 2018 and it’s Stunning – Futurism

Jaguar is releasing its Model X competitor in 2018 and the vehicle is absolutely gorgeous.

The SUV will be Jaguars very first electric car. Jaguar is smart to start with an SUV at a time where US consumers are consistentlyopting for more space.

The move puts Jaguar in direct competition with Teslas Model X, which has also experienced strong demand.In fact,Tesla soldroughly the same number of Model X SUVs (11,550) as Model S sedans (13,450) in the first quarter.

Heres what you need to know about Jaguars very first electric car:

Behold: Jaguars I-PACE, a five-seat SUV. Here it looks somewhat similar to Teslas Model X.

See what I mean?

The I-PACE is a preview of Jaguars electric, five-seat production car coming in 2018. That production car will be Jaguars first ever battery-powered vehicle. The brand new red I-PACE debuted at the Geneva Motor Show in March.

The car features a cab-forward design. Jaguar was able to execute this design because the car doesnt need an engine upfront. Jaguar said in a statement that taking a cab-forward design approach frees up room in the interior to make it more spacious.

The I-PACEs design is why many will consider the vehicle a crossover SUV. It has a compact body and is fairly low to the ground for a traditional SUV, but it still seats five while offering plenty of cargo space.

The Jaguar I-PACE has the same suspension system as the F-PACE, whichBusiness Insiders Matt DeBordcalled the most beautiful SUV on planet Earth in 2015.Jaguar has admitted the design it chose is unique in that sense.

The I-PACE Concept is, however, something altogether new: not a traditional sports car, saloon or SUV and absolutely not a traditional Jaguar, the automaker wrote in a press statement.

The car comes with a 90 kWh battery pack that powers two, 200 hp electric motors sitting over each axle.

Jaguar claims the car has a range of 220 miles, allowing it to compete most closely with the Model X 75D that offers 237 miles of range and starts at $85,500.

Theres no word on how much the Jaguar electric SUV will cost yet, so its hard to really compare it to the competition just yet. But Joe Eberhardt, CEO of Jaguar Land Rover North America, said in a Business Insider interview it will be comparable to luxury offerings from brands like Porsche.

AsBusiness Insiders Benjamin Zhangpointed out, that meansyoure looking at an asking price north of $50,000, which, again, not to beat a dead horse, really places it as a competitor with the luxury Model X in both offerings and price.

Jaguar said the car will offer 400 hp and 516 lb./ft. of torque, allowing it to accelerate to 60 mph in 4 seconds. That outpaces the Model X 75D and 90D, which can accelerate to 60 mph in 6 seconds and 4.8 seconds, respectively.

The I-PACE comes with a rear spoiler and a full-length panoramic sunroof.

Using a 50 kW DC rapid charger, it will charge the car in two hours.

The interior itself is striking. The seats are made of fine Windsor leather that matches the light color palette used inside.

The cockpit comes with two touchscreens on the center console.

The traditional drivers instrument was also replaced with a virtual screen that can be controlled using buttons on the steering wheel. The buttons offer haptic feedback when in use.

Heres another shot of the cockpit, which was finished with dark walnut veneers.

Its easy to see the attention to detail, from the stitching on the seats

To the seamless integration of metal and wood

To Jaguars personal engraving etched with laser on the instrument panels wood surface.

From what we know about the car so far, it seems Jaguars car has the potential to be a real contender in the electric car space when it arrives in 2018.

View original post here:

Jaguar is Releasing its Tesla Rival in 2018 and it's Stunning - Futurism

An Anonymous Ether Trader Just Made $200 Million in One Month – Futurism

In Brief An unknown cryptocurrency trader reportedly made more than $200 million in earnings in just over one month. The anonymity of cryptocurrencies, however, raises a lot of questions about the use of bitcoin and ether in the mainstream. 0x00A651D43B6e209F5Ada45A35F92EFC0De3A5184

Nope, that header isnt a typo. Thats the identification code for the virtual wallet of an anonymous cryptocurrency trader thats made more than $200 million in just over a month. Supposedly, this unknown trader was able to raise their cryptocurrency assets from $55 million to $283 million in that short span of time; a 413 percent accumulated profit from Ethereum blockchains digital money, ether.

In an Instagram post, someone (or maybe several people)purporting to be the trader in question said, I get many private messages asking how much ether I have. One of the cool things about Ethereum is that all wallets around the world are transparent and open for everyone to see. And this is my wallets savings.

While the amount of earnings from cryptocurrency trading is incredible, it isnt at all impossible. Recently, the values of both bitcoin and ether have been going up. The total value of cryptocurrencies reached an all-time high on June 6 when it surpassed$100 billion,according to Bloomberg.

Faced with the growth of cryptocurrencies, experts are askingwhether anonymity is beneficial or not. Its certainly one of the key reasonscryptocurrencies are becoming so popular. One of its more important features is that you dont have identities tied to this, Spencer Bogart, research head at venture firm Blockchain Capital, said inBloombergThis financial privacy is an important characteristic.

Thatsalso the source of some of its troubles, though: there have been a handful of cyberattacks that asked for ransom inbitcoin, and that trend could continue as it becomes more widely used. The credibility of virtual currencies will not rise if they are used for criminal purposes, adraft online currency legislation by the European Parliament noted. In this context, anonymity will become more a hindrance than an asset for virtual currencies.

To this end, would tying digital wallets to identifiable persons be a problem for a mainstream adoption of cryptocurrencies? For a cryptocurrency like ether which is used to pay for applications that run on the Ethereum blockchain it may not be such a big deal. It could evenhelp ether avoid having its reputation sullied by cyberattacks like bitcoin. At present, ether seems to bemoving into themainstream. The rise of Initial Coin Offering (ICO) is helping, and Ethereum is working to make their transactions even more efficient and powerful.

For now, though, it wouldnt hurt to be careful. As Peter Denious from Aberdeen Asset Management told Bloomberg, A lot of lessons will be learned. A lot of money will be lost before a lot of money can be made.

Read more:

An Anonymous Ether Trader Just Made $200 Million in One Month - Futurism

Scientists Just Teleported a Photon from Earth to Orbit for the First … – Futurism

In BriefResearchers from China successfully teleported a photon fromEarth to a satellite 500 km away. The work is an essential steptowards establishing a global-scale quantum internet. A Quantum Record

Not long ago, in the early 1990s, scientists only speculated that teleportation using quantum physics could be possible. Since then, the process has become a standard operation in quantum optics labs around the world. In fact, just last year, two separate teams conducted the worlds first quantum teleportation outside of a laboratory.

Now, researchers in China have taken the process a few steps further: theysuccessfully teleported a photon from Earth to a satellite orbiting more than 500 km (311 mi) away.

The satellite, called Micius, is a highly sensitive photo receiver capable of detecting the quantum states of single photons fired from the ground. Micius was launched to allow scientists to test various technological building blocks for quantum feats including entanglement, cryptography, and teleportation.

This teleportation feat was announced as one of the first results of these experiments. Not only did the team teleport the first object everfrom the ground to orbit, they also created the first satellite-to-ground quantum network, smashing the record for the longest distance for which entanglement has been measured.

Long-distance teleportation has been recognized as a fundamental element in protocols such as large-scale quantum networks and distributed quantum computation, says the Chinese team to MIT Technology Review.Previous teleportation experiments between distant locations were limited to a distance on the order of 100 kilometers, due to photon loss in optical fibers or terrestrial free-space channels.

What comes to mind when you think of teleportation?

Your brain might conjure images of Scotty beaming up the Enterprise crew in Star Trek, but its actually quite a different process than sci-fi films present.

Quantum teleportation relies on quantum entanglement a situation where one set of quantum objects (such as photons) form at the same instant and point in space. In this way, they share the same existence. This shared existence continues even when the photons are separated meaninga measurement on one immediately influences the state of the other, regardless of the distance between them.

This link can be used to transmit quantum information by downloading the information associated with one photon over an entangled link to another photon. This second photon takes on the identity of the first.

Voil. Teleportation.

In this particular instance, the Chinese team created entangled pairs of photons on the ground at a rate of about 4,000 per second. They then beamed one of these photons to the satellite, and kept the other photon on the ground. Finally, they measured the photons on the ground and in orbit to confirm that entanglement was taking place.

Its worth noting that there are some limits to this technology. Transporting anything large, for instance, is a ways off. In theory, theres also no maximum transportation distance, but entanglement is fragile, and the links can easily be broken.

Despite these limits, this research paves the way for even more ambitious studies of quantum teleportation. This work establishes the first ground-to-satellite up-link for faithful and ultra-long-distance quantum teleportation, an essential step toward global-scale quantum internet, says the team.

Read the original here:

Scientists Just Teleported a Photon from Earth to Orbit for the First ... - Futurism

Report: The US Will Exceed Its Paris Accord Goals Despite Trump’s Official Withdrawal – Futurism

In Brief A report by analysts from Morgan Stanley confirms a bright future for renewable energy. According to the report, the global adoption trend is fueled by the decreasing cost of renewables and the more attractive economic options it presents when compared to fossil fuels. An Unstoppable Trend

After U.S. president Donald Trump decided to pull the country out of the Paris Climate Agreement, many expected a reduction in the nations efforts to transition to clean and sustainable energy. That hardly seems the case now, however, as a number of U.S. states and even private institutions have decided to pursue initiativesthat reinforce those outlined in the international climate deal.

In Renewable Energy: What Cheap, Clean Energy Means for Global Utilities, a report published Thursday by financial services firmMorgan Stanley, analysts confirm that renewable energy is fast becoming the cheapest option.

Numerous key markets recently reached an inflection point where renewables have become the cheapest form of new power generation, the report noted. A dynamic we see spreading to nearly every country we cover by 2020.The report continued:

By our forecasts, in most cases favorable renewables economics, rather than government policy, will be the primary driver of changes to utilities carbon emissions levels. For example, notwithstanding president Trumps stated intention to withdraw the U.S. from the Paris climate accord, we expect the U.S. to exceed the Paris commitment of a 26-28% reduction in its 2005-level carbon emissions by 2020.

Indeed, the cost of renewables particularly solar has recently decreasedsignificantly, with the price of solar panels dropping by 50 percent in just two years, according to the report. This certainly makes reaching the carbon emission limitsset by the historic climate accord much easier, and the increased affordability is helping major polluters like India and China step uptheir renewable energy efforts.

The impact ofrenewable energy adoption extends beyondthe environment it also benefits the economy.

Renewables are providing better investment opportunities for utility companies while loweringcosts for consumers. The ability to lower customer bills from utilizing low-cost renewables can improve utilities regulatory environment and provide related investment opportunities in grid modernization initiatives, the analysts wrote. Aside from this, renewables are also generating more jobs than their fossil fuel counterparts in the U.S., they account for even more jobs than tech giants Google, Apple, and Facebook combined.

So, despite the U.S. officially withdrawing from the Paris Climate Agreement, the Morgan Stanley analysts believe that industries in the country will continue to see renewable energy as the more economically attractive and environmentally sound alternative to fossil fuels. Not even politics can stop this trend.

Read more:

Report: The US Will Exceed Its Paris Accord Goals Despite Trump's Official Withdrawal - Futurism

Martin Luther King Jr. Got the Presidential Medal of Freedom 40 Years Ago. That Timing Was No Coincidence – TIME

President Carter kisses Coretta Scott King, widow of civil rights leader Dr. Martin Luther King, Jr., at the White House, July 12, 1977, after he presented the Medal of Freedom to her on behalf of her late husband. John DurickaAP

When the civil-rights leader Martin Luther King Jr. was assassinated in 1968, he was already a national icon. But it would take nearly a decade more before he was awarded the Presidential Medal of Freedom, the nation's highest civilian honor. He was given the posthumous medal by President Jimmy Carter on July 11, 1977 precisely 40 years ago Tuesday for being, in Carter's words, the "conscience of a generation" who "made our nation stronger because he made it better."

Carter's decision to give King the medal came nearly a decade after the activist's death, but the timing made sense in the context of American politics at the time. The award was part of Carter's first round of Presidential Medal of Freedom selections, and many saw it as one way for Carter who had won more than 80% of the African-American vote in 1976 to acknowledge the voters who put him in office in the first place.

Not that his outreach to African Americans started with the election. He had become famous for declaring that "quite frankly that the time for racial discrimination is over" during his inaugural address as the governor of Georgia in 1971, and unveiled a portrait of Martin Luther King Jr. in the Georgia state capitol building in 1974. He was also the first Georgia Governor to appoint African Americans to many prominent state posts. "Nowhere can the promise and the serious problems of the emerging South be seen as readily as in Jimmy Carter 's state of Georgia," TIME declared in a cover story on how Carter represented change in the region.

Get your history fix in one place: sign up for the weekly TIME History newsletter

When Carter ran for president, he was predicted to easily win the black vote, thanks in part to ties to King's life and legacy. Andrew Young, the Georgia Congressman and former aide to Martin Luther King Jr., became a key liaison to black leaders, regaling church-goers with stories about how Carter lived next door to a black bishop whom he prayed with. The Rev. Martin Luther King Sr. delivered invocations at the Democratic National Convention. And, as now-Rep. John Lewis, who then ran the Atlanta-based Voter Education Project, pointed out to TIME, black support for Carter was a vote against one of his primary challengers, the segregationist former Alabama Governor George Wallace.

So it was no surprise that when Carter won the election, black leaders and the press were quick to look to the work of Martin Luther King Jr. "I wish Lord, how I wish Martin were alive today," Lewis said afterward. "He would be very, very happy. Through it all, the lunch-counter sit-ins, the bus strike, the marches and everything, the bottom line was voting."

And Carter acknowledged on myriad occasions, including upon receiving the Nobel Peace Prize, that his political career was made possible by the work of civil-rights leaders like King.

But the Presidential Medal of Freedom wasn't just about acknowledging work that had been done in the past. Accepting the award, the activist's widow Coretta Scott King pointed out that the decision to give her late husband the medal was symbolic of a national shift that, she hoped, would continue into the future. "It is highly significant," she said , "that you, Mr. President, a white Southerner, would become the first American President to recognize the importance of Martin Luther King, Jr.'s contributions to the human rights movement in this country."

Read the original:

Martin Luther King Jr. Got the Presidential Medal of Freedom 40 Years Ago. That Timing Was No Coincidence - TIME

Freedom Caucus chair threatens shutdown over border wall – Axios – Axios

Here are the political realities:

Conservatives will push for a repeal-only bill next. Unlike Senate Majority Leader Mitch McConnell, conservative groups were thrilled when President Trump tweeted that the Senate should try the repeal-first strategy. Vice President Mike Pence backed up that view on Rush Limbaugh's show yesterday: "We ought to just repeal only" if the Senate bill fails.

In the conservative groups' view, nearly all congressional Republicans already voted for a 2015 budget bill that repeals most of the Affordable Care Act so they should just pass that again. (In reality, the only way McConnell is likely to put that vote on the floor is to end the issue, even if it fails.)

If that vote doesn't happen, they'll hammer GOP leaders for not living up to their repeal promises and if moderate Republicans don't vote for it, they'll get an earful, too. "They'd have to explain why they're damned liars" after campaigning on repeal for seven years, said Jason Pye, vice president of legislative affairs for FreedomWorks.

The individual insurance market will still need help. It's not as if it's healthy right now. The Centers for Medicare and Medicaid Services reported yesterday that there was a 38 percent drop in the number of health insurers who filed to offer Affordable Care Act health insurance next year.

The fate of insurer subsidies still has to be resolved. The Trump administration won't want to keep paying for the cost-sharing subsidies for low-income customers without funding from Congress. So Congress would have to decide whether to fund the subsidies on its own.

The ACA will be run by an administration that hates it. By now, HHS Secretary Tom Price and CMS administrator Seema Verma have spent so much time promoting the law's failures that they'd have trouble switching gears and trying to make the law work.

Any bipartisan talks will be small ball. Even if moderate Democrats agree to start negotiating a "repair bill" with Republicans, the only ideas they've mentioned so far are relatively narrow, like Sen. Tim Kaine's proposal to create a permanent reinsurance program for the individual market.

Link:

Freedom Caucus chair threatens shutdown over border wall - Axios - Axios

The ironic state of freedom without democracy – The Hill (blog)

July 3 marked the 169th anniversary of the United States Virgin Islands Emancipation Day. In 1848, 15 years before President Lincoln signed the Emancipation Proclamation, enslaved Virgin Islanders under Danish rule organized and executed their own armed rebellion and won their freedom from chattel slavery. Those people of the Virgin Islands and Haiti executed the only successful violent overthrows by those enslaved in the Western Hemisphere.

Virgin Islanders then spent a decade as citizens without a country, and now, alongside fellow territorial residents, hold no electoral votes and have no voting representation in Congress. Disenfranchisement in territories was originally a temporary step on the path toward statehood, but it has become a means to maintain the doctrine established by the Plessy v. Ferguson-era Supreme Court of separate and unequal status for the overseas territories. A federal appeals court decision, the Obama administration brief in Tuaua v. United States in 2015 and Congresss unwillingness to grant equal treatment requests made by territorial representatives all uphold that unequal status.

As a consequence of this disparate treatment, the Virgin Islands does not receive the same proportion of support in federal dollars as do states for school funding, roads and healthcare. The federal government matches 14 cents to every dollar of territorial funds but 30 cents to every dollar of other state funds.

In 1917, Virgin Islanders came to Washington to petition for not only citizenship, but also the responsibilities thereof, demanding to be included in the draft, committing our sons to defend this country. This tradition of patriotism continues today, with Virgin Islanders giving the ultimate sacrifice in military conflicts at three times the national average. These brave service members fight for a commander in chief they do not elect and protect the ideals of a nation that are not fully extended to them and their families.

Our territorial status is eerily similar to the status of the original 13 colonies. The colonists we commemorate every year revolted and wrote the Declaration of Independence because they were controlled by a government in which they held no representation. Today, territorial residents face the same treatment. How can we herald the actions of our Founding Fathers while simultaneously depriving fellow Americans of the same rights those Founding Fathers fought so hard to achieve? Just as the colonists, we are subjected to the laws of an un-representational government. But just as the colonists, we will not stop fighting for the same representation that every other great American enjoys. A people who have made great contributions to this country including Alexander Hamilton, Denmark Vessey, and Tim Duncan still do not have equal citizenship. Democracy is not complete.

Plaskett represents the United States Virgin Islands at-large district in the United States House of Representatives. Plaskett currently serves on the House Committee on Agriculture and the House Committee on Oversight and Government Reform. Plaskett is the ranking member on the Oversight Subcommittee on the Interior, Energy, and Environment.

The views expressed by this author are their own and are not the views of The Hill.

See the article here:

The ironic state of freedom without democracy - The Hill (blog)

A Paean To Freedom In Poland – The Daily Caller

President Trumps speech in Warsaw was a remarkable paean to freedom. In words proud and strong he celebrated the human spirit. He quoted Polish martyr, Bishop Michael Kozal: More horrifying than a defeat of arms is a collapse of the human spirit.

In that same city 38 years before him Pope John Paul II, the most potent moral force of the 20th Century, celebrated a mass for the Polish people. One million people gathered to pray. One million strong they shouted, We want God.

Just as freedom cannot survive without faith, communism cannot survive when faith exists. One year later, in their pews and on their knees, the Poles prayed silently to their communist oppressors. In a single voice they said, You may take our state. You may take our freedom. You may not take our God.

From those humble pews they rose and took to the streets in the shipyard of Gdansk and Solidarity was born.

My wife, Lynne, and I were in Paris on that August day in 1980. We were scheduled to fly to London, but all flights had been cancelled due to the disruption in Gdansk. The trains were packed and the best we could do was catch a train to Oostende, Belgium and then a ferry to Folkestone, England.

It was well after midnight. People on the boat were leaning against walls and sitting on the floors. The excitement was tempered by anxiety. Something big was happening in Europe. No one knew quite what it portended, but there was electricity in the air.

In Folkestone we rented a car to begin a weeklong drive through England. A few nights later, in a very small and very old hotel in Hereford, we dressed for dinner. (Yes. We did that then.)There was only one customer in the dining room. A short rotund little man sat at the end of the bar chatting with the bartender. I had just been watching cricket on television while dressing and had no clue as to the rules of the game. He was a huge cricket fan and patiently explained the rules to Lynne and me.

He may have been stretching the story out a bit because I was buying his drinks. After he had consumed three drinks I was more confused than when he started and changed the subject to what was happening in Poland. He got very pensive. It is, he said ponderously, the beginning of the end of the Soviet Union. I thought that a bit much, but nine years and three months later the Soviet Union was no more.

The Poles are leading again today. They hold their values dear and believe theyre worth protecting at their borders. President Trump addressed those borders: For two centuries, Poland suffered constant and brutal attacks.But while Poland could be invaded and occupied, and its borders even erased from the map, it could never be erased from history or from your hearts.In those dark days, you have lost your land but you never lost your pride.

The borders are back and Poland refuses to yield to the pressure of the Eurozone to obfuscate them. They refuse to allow the invasion of foreigners. In the past 3 years there have been 28 events of terror from Belgium to France, England, Germany, Denmark, Sweden, Canada and the United States. There have been none in Poland.

It is the natural course of events for humans to choose to bring fairness and equality to the forests by cutting down the taller trees so that they will have no advantage to the sun over the rest. Similarly, the nations of the Eurozone would have Poland lower itself by opening its borders to share equally in the carnage from terrorism. Will Poland succumb? Will they have the will to maintain their borders and their values?

The president made it clear in Warsaw that our challenge is not of weaponry or strategy or might. It is a challenge of the will.

The fundamental question of our time is whether the West has the will to survive. Do we have the confidence in our values to defend them at any cost? Do we have enough respect for our citizens to protect our borders? Do we have the desire and the courage to preserve our civilization in the face of those who would subvert and destroy it?

In Warsaw President Trump urged Poland to lead the way for free nations across the globe once again. Let us welcome strangers to our shores, but let us welcome only those who want to share our values as well as our largesse.

If you would like to be added to John Linders distribution list please send your email address to: [emailprotected] or follow on Twitter: @linderje

Read more:

A Paean To Freedom In Poland - The Daily Caller